Morgan Stanley analyst Judah Frommer raised the firm’s price target on PTC Therapeutics (PTCT) to $94 from $92 and keeps an Overweight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics upgraded to Buy from Hold at TD Cowen
- PTC Therapeutics reports Q1 EPS (3c) vs. ($10.04) last year
- PTC Therapeutics raises 2026 revenue view to $1.08B-$1.18B, consensus $990.78M
- PTC Therapeutics Lifts 2026 Outlook on Sephience Momentum
- Tazeen Ahmad Reiterates Buy on Strengthened Votoplam Profile and Sephience Momentum; Keeps $93 Price Target Unchanged